Euro-Med Laboratories Phil Past Earnings Performance
Past criteria checks 4/6
Euro-Med Laboratories Phil's earnings have been declining at an average annual rate of -13.9%, while the Pharmaceuticals industry saw earnings growing at 11.2% annually. Revenues have been declining at an average rate of 4.9% per year. Euro-Med Laboratories Phil's return on equity is 5%, and it has net margins of 5.5%.
Key information
-13.9%
Earnings growth rate
-13.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -4.9% |
| Return on equity | 5.0% |
| Net Margin | 5.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Euro-Med Laboratories Phil makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,264 | 290 | 1,209 | 0 |
| 30 Sep 23 | 4,870 | 256 | 1,162 | 0 |
| 30 Jun 23 | 4,717 | 222 | 1,149 | 0 |
| 31 Mar 23 | 4,562 | 211 | 1,091 | 0 |
| 31 Dec 22 | 4,224 | 200 | 1,025 | 0 |
| 30 Sep 22 | 3,611 | 175 | 1,006 | 0 |
| 30 Jun 22 | 3,579 | 172 | 986 | 0 |
| 31 Mar 22 | 3,579 | 169 | 985 | 0 |
| 31 Dec 21 | 3,587 | 169 | 991 | 0 |
| 30 Sep 21 | 3,581 | 193 | 1,030 | 0 |
| 30 Jun 21 | 3,534 | 200 | 967 | 0 |
| 31 Mar 21 | 3,438 | 191 | 978 | 0 |
| 31 Dec 20 | 3,829 | 210 | 1,045 | 0 |
| 30 Sep 20 | 5,698 | 331 | 1,377 | 0 |
| 30 Jun 20 | 5,796 | 347 | 1,428 | 0 |
| 31 Mar 20 | 5,953 | 383 | 1,407 | 0 |
| 31 Dec 19 | 5,688 | 389 | 1,334 | 0 |
| 31 Dec 18 | 5,208 | 374 | 1,161 | 0 |
| 31 Dec 17 | 5,143 | 345 | 1,101 | 0 |
| 31 Dec 16 | 4,830 | 305 | 1,084 | 0 |
| 30 Sep 16 | 4,699 | 273 | 1,000 | 0 |
| 31 Dec 15 | 4,462 | 232 | 956 | 0 |
| 31 Dec 14 | 4,704 | 207 | 937 | 0 |
| 31 Dec 13 | 4,567 | 189 | 912 | 0 |
Quality Earnings: EURO has high quality earnings.
Growing Profit Margin: EURO's current net profit margins (5.5%) are higher than last year (4.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EURO's earnings have declined by 13.9% per year over the past 5 years.
Accelerating Growth: EURO's earnings growth over the past year (45.1%) exceeds its 5-year average (-13.9% per year).
Earnings vs Industry: EURO earnings growth over the past year (45.1%) exceeded the Pharmaceuticals industry 5.9%.
Return on Equity
High ROE: EURO's Return on Equity (5%) is considered low.